This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gordon, K. A.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gordon, K. A.
Right arrow Articles by Jones, R. N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2001, p. 3599-3600, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3599-3600.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Antimicrobial Susceptibility Testing of Clinical Isolates of Bordetella pertussis from Northern California: Report from the SENTRY Antimicrobial Surveillance Program

Kelley A. Gordon,1,2 Judy Fusco,3 Douglas J. Biedenbach,1,2 Michael A. Pfaller,1 and Ronald N. Jones1,2,*

University of Iowa College of Medicine, Iowa City, Iowa 522421; The Jones Group/JMI Laboratories, North Liberty, Iowa 523173; and The Kaiser-Permanente Regional Laboratory, Northern California, Berkeley, California 947042

Received 12 October 2000/Returned for modification 2 June 2001/Accepted 29 August 2001

Reports of an increased clinical incidence of pertussis and the development of resistance by Bordetella pertussis to erythromycin prompted the collection and testing of recent clinical isolates from patients in northern California against a range of antimicrobial agents by the Etest (AB BIODISK, Solna, Sweden) method. All isolates were fully susceptible to all eight agents tested (MIC, <= 0.38 µg/ml), including newer fluoroquinolones, such as gatifloxacin (MIC of which 90% of the isolates tested are inhibited, 0.006 µg/ml), which may be used in cases of adolescent or adult pertussis. Continued surveillance of B. pertussis isolates appears to be a prudent practice.

* Corresponding author. Present address: Suite A, 345 Beaver Creek Centre, North Liberty, Iowa 52317. Phone: (319) 665-3370. Fax: (319) 665-3371. E-mail: ronald-jones{at}jmilabs.com.

Antimicrobial Agents and Chemotherapy, December 2001, p. 3599-3600, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3599-3600.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Ohtsuka, M., Kikuchi, K., Shimizu, K., Takahashi, N., Ono, Y., Sasaki, T., Hiramatsu, K. (2009). Emergence of Quinolone-Resistant Bordetella pertussis in Japan. Antimicrob. Agents Chemother. 53: 3147-3149 [Abstract] [Full Text]  
  • Yao, S.-M., Liaw, G.-J., Chen, Y.-Y., Yen, M.-H., Chen, Y.-H., Mu, J.-J., Chiang, C.-S. (2008). Antimicrobial susceptibility testing of Bordetella pertussis in Taiwan prompted by a case of pertussis in a paediatric patient. J Med Microbiol 57: 1577-1580 [Abstract] [Full Text]  
  • Bourgeois, N., Ghnassia, J.-C., Doucet-Populaire, F. (2003). In vitro activity of fluoroquinolones against erythromycin-susceptible and -resistant Bordetella pertussis. J Antimicrob Chemother 51: 742-743 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»